133 related articles for article (PubMed ID: 36933759)
21. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
22. Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).
Runge HFP; Lacy S; Barrans S; Beer PA; Painter D; Smith A; Roman E; Burton C; Crouch S; Tooze R; Hodson DJ
Br J Haematol; 2021 Jan; 192(1):216-220. PubMed ID: 33010029
[No Abstract] [Full Text] [Related]
23. L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.
Zhang JY; Zhang PP; Zhou WP; Yu JY; Yao ZH; Chu JF; Yao SN; Wang C; Lone W; Xia QX; Ma J; Yang SJ; Liu KD; Dong ZG; Guo YJ; Smith LM; McKeithan TW; Chan WC; Iqbal J; Liu YY
Clin Cancer Res; 2019 Jul; 25(13):4168-4178. PubMed ID: 30824586
[TBL] [Abstract][Full Text] [Related]
24. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
25. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
26. Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Lee JY; Kang M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Song KH; Kim ES; Kim HB; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
Mycoses; 2021 Jan; 64(1):60-65. PubMed ID: 32970331
[TBL] [Abstract][Full Text] [Related]
27. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
[TBL] [Abstract][Full Text] [Related]
28. [Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance].
Bouabdallah S; Mariko ML; Besson J; Dellis O
Med Sci (Paris); 2021 Apr; 37(4):406-408. PubMed ID: 33908862
[No Abstract] [Full Text] [Related]
29. [A comparison of R-CHOP and R-DA-EPOCH as a first-line regimen treatment of diffuse large B cell lymphoma with non-GCB subtypes: a retrospective study].
He ZY; Yu WJ; Suo SS; Wang JH; Meng HT; Mai WY; Wei JY; Yang M; Mao LP; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):346-348. PubMed ID: 35680636
[No Abstract] [Full Text] [Related]
30. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
32. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.
Bewarder M; Kaddu-Mulindwa D; Kos IA; Lesan V; Held G; Poeschel V; Thurner L; Bittenbring JT; Schmitz N; Truemper L; Pfreundschuh M; Christofyllakis K; Loeffler M; Altmann B; Ziepert M
Haematologica; 2023 Oct; 108(10):2844-2849. PubMed ID: 36815369
[No Abstract] [Full Text] [Related]
33. Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
Knörr F; Zimmermann M; Attarbaschi A; Kabíčková E; Maecker-Kolhoff B; Ruf S; Kühnle I; Ebinger M; Garthe AK; Simonitsch-Klupp I; Oschlies I; Klapper W; Burkhardt B; Woessmann W
Haematologica; 2021 Dec; 106(12):3232-3235. PubMed ID: 34498443
[No Abstract] [Full Text] [Related]
34. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
35. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
[No Abstract] [Full Text] [Related]
36. Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
Lim KJC; Filshie R
Lancet Haematol; 2023 Dec; 10(12):e942-e943. PubMed ID: 37922924
[No Abstract] [Full Text] [Related]
37. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
Salles G; de Jong D; Xie W; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Calaminici M; Sander B; Thorns C; Campo E; Molina T; Lee A; Pfreundschuh M; Horning S; Lister A; Sehn LH; Raemaekers J; Hagenbeek A; Gascoyne RD; Weller E
Blood; 2011 Jun; 117(26):7070-8. PubMed ID: 21536860
[TBL] [Abstract][Full Text] [Related]
38. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract][Full Text] [Related]
39. [Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases].
Hu RH; Sun WL; Zhao H; Hui WH; Guo YX; Wan SG; Su L
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(9):1291-1294. PubMed ID: 27687667
[TBL] [Abstract][Full Text] [Related]
40. Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Younes S; Yoo C; Wignarajah A; Jin M; Guo HH; Gupta NK; Natkunam Y; Advani RH; Hoppe RT
Leuk Lymphoma; 2021 Aug; 62(8):1840-1849. PubMed ID: 33622155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
